Literature DB >> 21047252

Newly identified events in the RE-LY trial.

Stuart J Connolly, Michael D Ezekowitz, Salim Yusuf, Paul A Reilly, Lars Wallentin.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 21047252     DOI： 10.1056/NEJMc1007378

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  171 in total

1.  MEDEX South Carolina: a progress report.

Authors:  K J Buhmeyer; A R Hutson
Journal:  J S C Med Assoc       Date:  1975-11

2.  Fast atrial fibrillation and caecal volvulus--a case report and evidence based management.

Authors:  Alexander Liu; Edward Nicol
Journal:  BMJ Case Rep       Date:  2011-12-20

Review 3.  Approach to the new oral anticoagulants in family practice: part 1: comparing the options.

Authors:  James Douketis; Alan David Bell; John Eikelboom; Aaron Liew
Journal:  Can Fam Physician       Date:  2014-11       Impact factor: 3.275

4.  [Anticoagulation for atrial fibrillation : the future has begun].

Authors:  M Moser; C Bode
Journal:  Internist (Berl)       Date:  2012-01       Impact factor: 0.743

Review 5.  Promise of factor Xa inhibition in atrial fibrillation.

Authors:  Sana M Al-Khatib; John H Alexander; Renato D Lopes; Kenneth W Mahaffey; Manesh R Patel; Christopher B Granger
Journal:  Curr Cardiol Rep       Date:  2012-02       Impact factor: 2.931

Review 6.  Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  John W Eikelboom; Jack Hirsh; Frederick A Spencer; Trevor P Baglin; Jeffrey I Weitz
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 7.  Direct thrombin inhibitors in cardiovascular disease.

Authors:  Kyle A Arsenault; Jack Hirsh; Richard P Whitlock; John W Eikelboom
Journal:  Nat Rev Cardiol       Date:  2012-05-01       Impact factor: 32.419

Review 8.  Optimal thromboprophylaxis following bioprosthetic aortic valve replacement: still a matter of debate?

Authors:  Muhammad I Mydin; Georgios Dimitrakakis; Jenan Younis; Justin Nowell; Thanos Athanasiou; Antonios Kourliouros
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-04-05

9.  Anticoagulation therapy. Dabigatran and risk of myocardial infarction.

Authors:  John W Eikelboom; Jeffrey I Weitz
Journal:  Nat Rev Cardiol       Date:  2012-03-13       Impact factor: 32.419

10.  Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles?

Authors:  Paul K L Chin; Jane W A Vella-Brincat; Murray L Barclay; Evan J Begg
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.